AU2927492A - Phenol derivatives as agonists of a cyclic amp dependent protein kinase - Google Patents
Phenol derivatives as agonists of a cyclic amp dependent protein kinaseInfo
- Publication number
- AU2927492A AU2927492A AU29274/92A AU2927492A AU2927492A AU 2927492 A AU2927492 A AU 2927492A AU 29274/92 A AU29274/92 A AU 29274/92A AU 2927492 A AU2927492 A AU 2927492A AU 2927492 A AU2927492 A AU 2927492A
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- group
- hereinbefore defined
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000556 agonist Substances 0.000 title description 5
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 title description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 title description 3
- 150000002989 phenols Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 251
- -1 P(Z) (OH) (OR2) Inorganic materials 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 229910006069 SO3H Inorganic materials 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000012025 fluorinating agent Substances 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- OIIFXPWZZKWODW-UHFFFAOYSA-N 5-(2,3-dipropoxyphenyl)-2-(2H-tetrazol-5-yl)phenol Chemical compound N1N=NN=C1C1=C(C=C(C=C1)C1=C(C(=CC=C1)OCCC)OCCC)O OIIFXPWZZKWODW-UHFFFAOYSA-N 0.000 claims description 4
- MEPFYHHKZLKVLW-UHFFFAOYSA-N P(OCC)(OC1=C(C=C(C=C1)C1=C(C(=CC=C1)OCCC)OCCC)O)=O Chemical compound P(OCC)(OC1=C(C=C(C=C1)C1=C(C(=CC=C1)OCCC)OCCC)O)=O MEPFYHHKZLKVLW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000004291 sulphur dioxide Substances 0.000 claims description 4
- 235000010269 sulphur dioxide Nutrition 0.000 claims description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 239000002585 base Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000003960 organic solvent Substances 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JUEFXJKFZOSHHN-UHFFFAOYSA-N (2,3-dipropoxyphenyl)boronic acid Chemical compound CCCOC1=CC=CC(B(O)O)=C1OCCC JUEFXJKFZOSHHN-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 150000005826 halohydrocarbons Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- JOMZOIIHYMEUBH-UHFFFAOYSA-N 3-(2,3-dipropoxyphenyl)phenol Chemical compound CCCOC1=CC=CC(C=2C=C(O)C=CC=2)=C1OCCC JOMZOIIHYMEUBH-UHFFFAOYSA-N 0.000 description 2
- YYDDNCLPNZEHNA-UHFFFAOYSA-N 4-(2,3-dipropoxyphenyl)-2-hydroxybenzaldehyde Chemical compound CCCOC1=CC=CC(C=2C=C(O)C(C=O)=CC=2)=C1OCCC YYDDNCLPNZEHNA-UHFFFAOYSA-N 0.000 description 2
- XPCBUTKSJCDMJQ-UHFFFAOYSA-N 4-(2,3-dipropoxyphenyl)-2-hydroxybenzonitrile Chemical compound CCCOC1=CC=CC(C=2C=C(O)C(C#N)=CC=2)=C1OCCC XPCBUTKSJCDMJQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101100454393 Homo sapiens LCOR gene Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100038260 Ligand-dependent corepressor Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000003295 lusitropic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- IIFCLXHRIYTHPV-UHFFFAOYSA-N methyl 2,4-dihydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1O IIFCLXHRIYTHPV-UHFFFAOYSA-N 0.000 description 2
- MXOIHNZTPXQGIR-UHFFFAOYSA-N methyl 4-(2,3-dipropoxyphenyl)-2-hydroxybenzoate Chemical compound CCCOC1=CC=CC(C=2C=C(O)C(C(=O)OC)=CC=2)=C1OCCC MXOIHNZTPXQGIR-UHFFFAOYSA-N 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- COABRICCWCYCPI-ZYLNUDMXSA-N (2s,3s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamin Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)O)C(C)C)CC1=CC=C(O)C=C1 COABRICCWCYCPI-ZYLNUDMXSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- XUIKECLBCZBUCM-UHFFFAOYSA-N 1,2-dipropoxybenzene Chemical compound CCCOC1=CC=CC=C1OCCC XUIKECLBCZBUCM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YMRIDJQAEZFTSC-UHFFFAOYSA-N 2,3-dihydro-1h-tetrazole Chemical group N1NC=NN1 YMRIDJQAEZFTSC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 1
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- JQXJBXVWVPVTOO-UHFFFAOYSA-L 4-diphenylphosphanylbutyl(diphenyl)phosphane;palladium(2+);dichloride Chemical compound Cl[Pd]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 JQXJBXVWVPVTOO-UHFFFAOYSA-L 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SJEPXFDQRCGUJA-UHFFFAOYSA-N [3-(2,3-dipropoxyphenyl)phenyl] diethyl phosphate Chemical compound CCCOC1=CC=CC(C=2C=C(OP(=O)(OCC)OCC)C=CC=2)=C1OCCC SJEPXFDQRCGUJA-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 201000010435 allergic urticaria Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- YDPLDMLRERBXAV-UHFFFAOYSA-N aluminum;triazide Chemical compound [Al+3].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] YDPLDMLRERBXAV-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical group [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- RQLKAKQYERUOJD-UHFFFAOYSA-N lithium;1,3,5-trimethylbenzene-6-ide Chemical compound [Li+].CC1=CC(C)=[C-]C(C)=C1 RQLKAKQYERUOJD-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010091504 malantide Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-M methanethiolate Chemical compound [S-]C LSDPWZHWYPCBBB-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical group CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
PHENOL DERIVATIVES AS AGONISTS OF A CYCLIC AMP DEPENDENT PROTEIN KINASE
The present invention relates to phenol derivatives,
processes for their preparation, intermediates in their preparation, their use as medicaments and to pharmaceutical compositions comprising them.
The compounds of this invention are agonists of a cyclic AMP- dependent protein kinase (cA-PrK) (see J. Biol. Chem., 1989, 264, 8443 - 8446) and are of use in combatting such
conditions where such agonism is thought to be beneficial. They are likely to have anti-proliferative, anti-aggregatory, cholesterol-lowering, smooth muscle relaxant, positive lusitropic, anti-allergic or anti-inflammatory activities. They are likely to be useful in the treatment of
cardiovascular diseases where there is a component of
diastolic failure, cancer, psoriasis, atheroschlerosis, thrombosis, re-stenosis, chronic reversible lung disease such as asthma and bronchitis, allergic disease such as allergic asthma,, allergic rhinitis and urticaria or gut motility disorders such as irritable bowel syndrome.
Accordingly the present, invention provides compounds of the formula (1) :
or pharmaceutically acceptable salts thereof, wherein :
R0 is OH or a bioprecursor thereof, R1 is A0CO2H, P(Z) (OH) (OR2), SO2H, SO3H or 5-tetrazolyl or a bioprecursor thereof,
A0 is CH2, CHF, CF2, CR3 (OR4) , CO or C (OR5) (OR6) ,
R2 is phenyl, C3-5Cycloalkyl, C3-5cycloalkylC1-4alkyl, or C1-8alkyl optionally substituted by C1-4alkoxy,
R3 is H, methyl or ethyl,
R4 is H or C1-3alkyl,
R5 and R6 are each C1-3alkyl or together form a 1,2- ethanediyl group or 1,3-propanediyl group,
Z is O or S, and
Ar is phenyl optionally substituted by one to three groups independently selected from C1-6alkyl, C2-6alkenyl, C1-6alkoxy, C3-6alkenyloxy, C3-6cycloalkyl,
C3-6cycloalkoxy, C1-6alkylthio, phenyl, phenylthio, benzyloxy, C1-6polyfluoroalkyl, C1-6polyfluoroalkoxy, halo, N(R7)2 or NHCOR7 wherein R7 is H or C1-6alkyl, or -X(CH2)nY- attached to adjacent carbon atoms of the phenyl ring wherein X and Y are independently CH2 or O and n is 1 to 3, wherein said C1-6alkyl, C2-6alkenyl or C1-6alkoxy groups can be independently substituted by OH, C1-6alkoxy, C3-6cycloalkyl, N(R7)2, CO2R7 or CON(R7)2.
Bioprecursors of the groups R0 and R1 are derivatives thereof which are convertible in vivo into the groups R0 and R1.
A suitable bioprecursor of the group R0 is OR8 wherein R8 is C1-4alkanoyl (for example acetyl), arylC1-4alkanoyl (for example phenyl C1-4alkanoyl such as benzoyl), arylsulphonyl (for example optionally substituted phenylsulphonyl or toluenesulphonyl) or C1-4alkylsulphonyl
(for example methylsulphonyl).
When R1 is A0CO2H a suitable bioprecursor is A0CO2R9 wherein R9 is an ester-forming group.
When R1 is P(Z) (OH) (OR2) a suitable bioprecursor is
P (Z) (OR2)2 wherein Z and R2 are as hereinbefore defined or P(Z) (OR2) (OR10) wherein R10 is an O-protecting group.
Suitable O-protecting groups include pivaloyloxymethyl, propionyloxymethyl and pivalolyloxycarbonyloxymethyl.
When R1 is 5-tetrazolyl, a suitable biopricursor is a
N-protected derivative thereof. Suitable N-protecting groups include pivalolyloxymethyl, propionyloxymethyl and
pivalolyloxycarbonyloxymethyl.
Alternatively bioprecursors of the groups R0 and R1 are those formed when R1 and R0 are linked together to form a cyclic structure such that R1-R0 is A1CO2 or A2OCH2O, in which :
A1 is CH2, CHF, CF2, CR3(OR4), CO or C(OR5) (OR6),
A2 is P(Z)OR2 or CR3(CO2R9), and
R2 to R6, R9 and Z are as hereinbefore defined.
Suitably R0 is hydroxy or OR8, preferably hydroxy. Suitably R1 is A0CO2H or A0CO2R9.
Suitably R1 is P (Z) (OH) (OR2) or P(Z) (OR2)2.
Suitably R1 is SO2H, SO3H or 5-tetrazolyl.
Suitably R1 and R0 are linked together such that R1-R0 is A1CO2.
Suitably R1 and R0 are linked together such that R1-R0 is A2OCH2O.
By the term alkyl is meant both straight- and branched- chain alkyl.
By the term Ci-gpolyfluoroalkyl is meant a C1-6alkyl group having at least one hydrogen replaced with fluoro, e.g. CF3 or CF2CF2H. Suitably R2 is methyl, ethyl, propyl, butyl, pentyl, hexyl, 2-methoxyethyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclopropylmethyl.
Suitably R3 is H, methyl or ethyl, preferably H or methyl.
Suitably R4 is H, methyl, ethyl or propyl, preferably H or methyl.
Suitably R5 and R6 are independently methyl, ethyl or propyl, preferably together they form a 1,2-ethanediyl group.
Preferably Z is O.
Suitably R9 is C1-4alkyl optionally substituted by hydroxy, e.g. 2-hydroxyethyl or arylC1-4alkyl (for example
phenylC1-4alkyl such as benzyl).
Suitably Ar is phenyl optionally mono-substituted by a group as hereinbefore defined, for example in the 2,3, or 4
positions by C1-6alkyl, C1-6alkoxy, C3-6alkenyloxy,
C1-6alkylthio, phenyl, phenylthio, benzyloxy, CF3, halo or NHCOR7.
Suitably Ar is phenyl di-substituted by any groups as
hereinbefore defined, for example in the 3,4-,3,5-,2,3-,2,4- or 2,5-, positions by groups independently selected from
C2-6alkenyl, C1-6alkoxy, C3-6cycloalkoxy, halo, -X(CH2)nY- or C1-6alkoxyC1-6 alkoxy. Suitably Ar is phenyl trisubstituted by any groups as
hereinbefore defined, for example in the 2,3,4-, 2,3,5-, or 3,4,5-positions by groups independently selected from
C2-6alkenyl, C1-6alkoxy or halo.
Examples of C1-6alkoxy include methoxy, ethoxy, propoxy, butoxy, or pentyloxy.
Examples of C1-6alkyl include methyl, ethyl, propyl, butyl, isobutyl or pentyl.
Examples of halo include fluoro, chloro, bromo or iodo.
Particular compounds of this invention include :
2-(5-tetrazolyl)-5-(2,3-dipropoxyphenyl)phenol, or ethyl 2-hydroxy-4-(2,3-dipropoxyphenyl)phenyl phosphonate, and pharmaceutically acceptable salts thereof.
This invention covers all tautomeric, geometric and optical isomeric forms of compounds of formula (1). Compounds of the formula (1) can form pharmaceutically acceptable base addition salts with metal ions, such as alkali metals for example sodium or potassium, or with an ammonium ion. In order to use a compound of the formula (1) or a
pharmaceutically acceptable salt thereof for the treatment of humans and other mammals it is normally formulated in
accordance with standard pharmaceutical practice as a
pharmaceutical composition.
Compounds of formula (1) and their pharmaceutically
acceptable salts may be administered in standard manner for the treatment of the indicated diseases, for example orally, sublingually, parenterally, transdermally, rectally, via inhalation or via buccal administration.
Compounds of formula (1) and their pharmaceutically
acceptable salts which are active when given orally or via buccal administration can be formulated appropriately in
dosage forms such as liquids, syrups, tablets, capsules and lozenges . An oral liquid formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include starch, celluloses, lactose, sucrose and magnesium stearate. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule, any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be
considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil or solubilising agent, for example
polyethylene glycol, polyvinylpyrrolidone, lecithin,
2-pyrrolidone, cyclodextrin, arachis oil, or sesame oil. A typical suppository formulation comprises a compound of formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream,
ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propellant such
as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
Each dosage unit for oral administration contains suitably from 0.001 mg/Kg to 30 mg/Kg, and preferably from 0.005 mg/Kg to 15 mg/Kg, and each dosage unit for parenteral
administration contains suitably from 0.001 mg/Kg to 10 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for oral administration is suitably about 0.001 mg/Kg to 120 mg/Kg, of a compound of formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, for example about 0.005 mg/Kg to 10 mg/Kg, of a compound of the formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The active ingredient may be administered as required for example from 1 - 8 times a day or by infusion. The compositions of the invention are agonists of a cA-PrK and are of use in combatting such conditions where such agonism is thought to be beneficial. Such conditions can be treated by administration orally, sublingually topically, rectally, parenterally or by
inhalation. For administration by inhalation dosages are controlled by a valve, are administered as required and for an adult are conveniently in the range 0.1 - 5.0 mg of a compound of the formula (1) or a pharmaceutically acceptable salt thereof. The compounds of this invention may be co-administered with other pharmaceutically active compounds, for example in combination, concurrently or sequentially. Conveniently the compounds of this invention and the other active compound or compounds are formulated in a single pharmaceutical
composition. Examples of compounds which may be included in pharmaceutical compositions with the compounds of the formula (1) are bronchodilators such as sympathomimetic amines for example isoprenaline, isoetharine, sulbutamol, phenylephrine and ephedrine or xanthine derivatives for example
theophylline and aminophylline, anti-allergic agents for example disodium cromoglycate, histamine H1-antagonists, drugs used in the treatment of cancer such as those which inhibit the synthesis of or inactivate DNA, for example methotrexate, fluoracil, cisplatin, actinomycin D, anti- atherschlerotic agents for example cholesterol lowering drugs such as HMGCoA reductase inhibitors, bile acid sequestrants, drugs for the treatment of psoriasis, for example retinoids, anthralin, anti-inflammatories for example cortiscosteroids, non-steroid anti-inflammatories such as aspirin,
antithrombotics for example dipyridamole, or fibrinolytic agents.
In another aspect the present invention provides a process for the preparation of compounds of the formula (1) or
pharmaceutically acceptable salts thereof, which process comprises : a) for compounds wherein R1 is A0CO2H or A0CO2R9 and : i) A0 is CR3 (OR4),
reacting in the presence of a strong base a compound of the formula (2) :
wherein R11 is methyl and Ar is as hereinbefore defined.
with a compound of the formula (3) :
R3COCO2R9 (3) wherein R3 and R9 are as hereinbefore defined to form a compound of the formula (4) :
wherein R12 is CR3(OH)CO2R9 and R3, R9, R11, and Ar are as hereinbefore defined and thereafter optionally reacting with a C1-3alkylating agent to form the corresponding compound wherein R12 is CR3 (OC1-3alkyl) CO2R9, ii) A0 is CO,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with a compound of the formula (5) :
R9O2CCO2R9 (5) wherein R9 is as hereinbefore defined to form a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11 and Ar are as hereinbefore defined, iii) A0 is CH(OH),
reacting a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a reducing agent to form the corresponding compound wherein R12 is CH(OH)CO2R9, iv) A0 is CH2,
reacting a compound of the formula (4) wherein R12 is COCO2H or COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a suitable reducing agent to form the corresponding compound wherein R12 is CH2CO2H, v) A0 is C(OR5) (OR6),
reacting a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a
C1-3alcohol, 1,2-ethanediol or 1,3-propanediol to form the corresponding compound wherein R12 is C(OR5) (OR6)CO2R9, vi) A0 is CF2,
reacting a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a fluorinating agent to form the corresponding compound wherein R11 is CF2CO2R9, or vii) A0 is CHF,
reacting a compound of the formula (4) wherein R12 is
CH(OH)CO2R9 and R9, R11, and Ar are as hereinbefore defined with a fluorinating agent to form the corresponding compound wherein R12 is CHFCO2R9, and thereafter optionally : º converting the group OR11 into OH º converting the group A0CO2R9 into AOCO2H; or b) for compounds wherein R1 is CH2CO2H,
converting a compound of the formula (6) :
wherein R13 is acetyl and Ar is as hereinbefore defined into the corresponding compound wherein R13 is CH2CO2H; or c) for compounds wherein R1 is CH(OR4)CO2H reacting a compound of the formula (4) wherein R12 is -CH(OH)CN with a C1-3alkylating agent and/or converting the group CN into CO2H, and optionally converting the group OR11 into OH; or d) for compounds wherein R1 is P(O)(OH)(OR2),
hydrolysing a compound of the formula (6) wherein R13 is P(O)(OR2)2 and R2, and Ar are as hereinbefore defined; or e) for compounds wherein R1 is P(S) (OH) (OR2), converting a compound of the formula (6) wherein R13 is P (O) (NHR14) (OR2) and R14 is phenyl or C1-4alkyl and Ar is as hereinbefore defined into the corresponding compound wherein R13 is
P(S) (OH) (OR2); or f) for compounds where R1 is SO3H,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with sulphury1 chloride or a chemical equivalent thereof and optionally converting the group OR11 into OH; or g) for compounds wherein R1 is SO2H,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with sulphur dioxide and optionally converting the group OR11 into OH; or h) for compounds wherein R1 is 5-tetrazolyl, reacting a compound of the formula (4) wherein R12 is cyano and R11 is as hereinbefore defined or benzenesulphonyl, or a compound of the formula (6) wherein R12 is cyano with an azide salt and thereafter if necessary converting the group OR11 into OH; or i) for compounds wherein R1 is as defined for compounds of the formula (1) reacting in the presence of a palladium catalyst a compound of the formula (7):
wherein Rb is a group R1 as hereinbefore defined or a precursor thereof and Ra is R0 or OR11 as hereinbefore defined and L1 is a leaving group with a compound of the formula (8):
ArB(OH)2 (8) or a chemical equivalent thereof wherein Ar is as
hereinbefore defined and then, if necessary, converting a precursor of R1 into R1 and/or converting the group OR11 into OH, and optionally thereafter : ° forming a bioprecursor of R0 and/or R1
° forming a pharmaceutically acceptable salt.
Suitably a compound of the formula (2) is reacted with a strong base such as lithium diisopropylamide, or a C1-4alkyl lithium or aryl lithium such as mesityl lithium in an organic solvent such as tetrahydrofuran, diethylether or
dimethoxyethane with cooling (-100° - 0°C) to form the anion thereof. The strong base may be formed in situ, for example by the addition of a C1-4alkyl lithium e.g. methyllithium followed by a catalytic quantity of diisopropylamine.
The anion of a compound of the formula (2) is suitably
reacted with, a compound of the formula (3) or a compound of the formula (5) in an organic solvent such as
tetrahydrofuran, diethylether or dimethoxyethane with cooling (-100° to 0°C) to form a compound of the formula (4) wherein R12 is CR3(OH)CO2R9 or COCO2R9 respectively. A suitable compound of the formula (3) is ethylpyruvate, or ethyl glyoxylate or a chemical equivalent thereof and a suitable compound of the formula (5) is diethyloxalate.
A compound of the formula (4) wherein R12 is CR3(OH)CO2R9 is suitably reacted with a C1-3alkylating agent such as
iodomethane, iodopropane or dimethylsulphate in the presence of a base such as sodium hydride or potassium hydroxide in an organic solvent such as dimethylformamide or
dimethylsulphoxide at elevated (e.g. 30 - 80°C) or preferably ambient temperature to form the corresponding compound wherein R12 is CR3 (OC1-3alkyl) CO2R9. When potassium
hydroxide is used as base the CO2R9 group may be directly converted to carboxy. A compound of the formula (4) wherein R12 is COCO2R9 is suitably reacted with a reducing agent such as sodium
borohydride, or diisobutylaluminium hydride in an organic solvent such as dichloromethane, a C1-4alcohol e.g. ethanol, or acetic acid or mixtures thereof at ambient or elevated temperature (e.g. 30 - 80°C), or with cooling (e.g. 0 - 5°C) to form the corresponding compound wherein R12 is
CH(OH)CO2R9.
A compound of the formula (4) wherein R12 is COCO2H or
COCO2R9 is suitably reacted with a reducing agent such as a zinc amalgam in hydrochloric acid in the absence of a solvent or in a solvent such as ethanol, acetic acid or dioxan and hydrogen chloride gas at ambient or elevated temperature
(e.g. 40-100°C) to form the corresponding compound wherein R12 is CH2CO2H. Under these reaction conditions the CO2R9 group is converted to carboxy.
A compound of the formula (4) wherein R12 is COCO2R9 is suitably reacted with a C1-3alcohol, 1,2-ethanediol or 1,3-propanediol in the presence of an acid catalyst such as
paratoluenesulphonic acid, concentrated sulphuric acid or anhydrous hydrogen chloride, at ambient or elevated
temperature to form the corresponding compound wherein R12 is C(OR5)(OR6)CO2R9.
A compound of the formula (4) wherein R12 is COCO2R9 or
CHOHCO2R9 is suitably reacted with a fluorinating agent such as diethylaminosulphur trifluoride in an organic solvent such as a halohydrocarbon or an ether such as glyme, or THF at ambient or elevated temperature (e.g. 30-60°C) to form the corresponding compound where R12 is CF2CO2R9 or CHFCO2R9 respectively.
A compound of the formula (4) wherein OR11 is methoxy can suitably be converted to the corresponding compound wherein OR11 is hydroxy by reaction with sodium iodide and
chlorotrimethylsilane in an organic solvent such as
acetonitrile, or a halohydrocarbon e.g. dichloromethane or chloroform at elevated (e.g. 30 - 80°C) or preferably ambient temperature. This method is particularly suitable for preparing compounds of the formula (1) wherein R1 is A0CO2R9 since the ester-forming group R9 is not hydrolysed under the reaction conditions. Another method utilises sodium
thiomethoxide in an organic solvent such as dimethylformamide at an elevated temperature for example 40 - 120°C. The more forcing conditions of this method are suitable for preparing compounds of formula (1) wherein R1 is A0CO2H.
A compound of the formula (4) wherein R12 is A0CO2R9 can suitably be converted to the corresponding compound wherein R12 is A0CO2H by reaction with an aqueous base such as sodium or potassium hydroxide at ambient or elevated temperature (e.g. 40 - 120°). This method is particularly suitable for preparing compounds of the formula (1) wherein R0 is methoxy since the OR11 group is not hydrolysed. Another hydrolysis method utilises aqueous acid such as concentrated
hydrochloric acid at an elevated temperature (e.g. 40 - 120°C) which provides directly compounds of the formula (1) wherein R0 is hydroxy and R1 is A0CO2H.
Suitably a compound of the formula (6) wherein R13 is acetyl is converted to the corresponding compound where R13 is CH2CO2H by reaction with sulphur and morpholine
at elevated temperature (e.g. 50 - 200°C), followed by hydrolysis with an aqueous base such as sodium hydroxide at elevated temperature, preferably at the reflux temperature of the reaction mixture. Suitably a compound of formula (4) where R12 is -CH(OH)CN is reacted with a C1-3alkylating agent as hereinbefore describe followed by reaction with aqueous mineral acid such as hydrochloric acid at ambient or elevated temperature
preferably at reflux in order to prepare the corresponding compound where R12 is CH(OC1-3alkyl) CO2H. The alkylation can be omitted if the corresponding compound where R12 is CH(OH)CO2H is desired. During the hydrolysis of the CN group the OR11 group may be converted to hydroxy. If not and if desired this group can be converted to hydroxy as
hereinbefore described.
A compound of the formula (4) wherein R12 is -CH(OH)CN can be prepared by reacting the corresponding compound wherein R12 is -CHO with a source of cyanide such as potassium cyanide in the presence of an acid such as hydrochloric acid preferably at ambient temperature.
A compound of the formula (4) or (6) where R12 or R13 is CHO is suitably prepared by reacting the corresponding compound wherein R12 or R13 is cyano with a suitable reducing agent such as diisobutylaluminium hydride followed by aqueous acidic work-up.
Suitably a compound of the formula (6) wherein R13 is
P(O)(OR2)2 is hydrolysed by reaction with an aqueous base such as sodium hydroxide optionally in a cosolvent such as a Cι_4alcohol at an elevated temperature (e.g. 40-100°C), preferably at the reflux temperature of the reaction mixture.
Suitably a compound of the formula (6) wherein R13 is
P(O) (NHR14) (OR2) is converted to the corresponding compound wherein R9 is P(S) (OH) (OR2) by reaction with a strong base such as sodium hydride in an organic solvent such as
dimethoxyethane at ambient or elevated temperature, (e.g. 40 - 100°C) followed by reaction with carbon disulphide.
Suitably the anion of a compound of the formula (2) prepared as hereinbefore described is reacted with sulphuryl chloride or a chemical equivalent thereof or with sulphur dioxide in an organic solvent such as tetrahydrofuran with cooling (- 100° - 0°C) to form after aqueous work-up a compound of the formula (4) wherein R12 is SO3H or SO2H respectively and OR11 is methoxy which if desired can be converted to the
corresponding compound wherein OR11 is hydroxy as
hereinbefore described.
A compound of the formula (4) wherein R12 is cyano or a compound of the formula (6) wherein R13 is cyano is suitably reacted with an azide salt such as ammonium, sodium or aluminium azide in an organic solvent such as
diethylformamide, dimethylsulphoxide, N-methylpyrrolidone or tetrahydrofuran at an elevated temperature e.g. 40-200°C, preferably at 100-150°C to form the corresponding
5-tetrazolyl compound. Preferably in a compound of the formula (4) OR1 1 is benzenesulphonyl which can be introduced in standard manner, for example by reacting the corresponding hydroxy compound with benzenesulphonyl chloride in the presence of a base such as triethylamine. This group can be removed in standard manner, for example by reaction with a base such as sodium hydroxide.
Suitably a compound of the formula (7) is reacted with a compound of the formula (8) in the presence of 1-50 mole %, preferably 2-10 mole %, of a palladium catalyst and a base such as triethylamine, sodium bicarbonate, or aqueous sodium carbonate and optionally lithium chloride in an organic solvent such as dimethylformamide, dimethoxyethane
acetonitrile, toluene, tetrahydrofuran, ethanol, or mixtures
thereof, at elevated temperature, (e.g. 30-150°C), preferably at the reflux temperature of the mixture. Suitably L1 is halo for example iodo, bromo or chloro or a
trifluoromethanesulphonate. Subsequently the OR11 group can be converted to hydroxy as hereinbefore described for
compounds of formula (4). Examples of palladium catalysts that can be used include: tetrakis(triphenylphosphine)palladium (Pd[PPh3]4),
bis(triphenylphosphine)palladium dichloride (Pd[PPh3]2Cl2), [1,4-bis-(diphenylphosphine)butane]palladium dichloride
(Pd(dppb)Cl2),
[1,3-bis-(diphenylphosphine)propane]palladium dichloride
(Pd(dppp)Cl2),
[1,2-bis-(diphenylphosphine)ethane]palladium dichloride
(Pd(dppe)Cl2),
bis(tri-o-tolylphosphine)palladium diacetate or dichloride (Pd(totp) (OAc)2 or Pd(totp)CI2), or
1,1 -bis(diphenylphosphine)ferrocinopalladium diacetate or dichloride (Pd[dppf](OAc)2 or Pd[dppf]Cl2).
By a chemical equivalent of a compound of the formula (8) is meant a reagent that can couple the Ar group onto the pyridyl ring of a compound of the formula (7). For example aryl stannanes can be used, such as ArSnMe3 which can suitably be prepared by reacting a suitable aryl halide (such as ArBr or ArI) with a base such as t-butyl lithium followed by reaction with a trimethyl tin halide (e.g. Me3SnCl). Alternatively the aryl halide can be reacted with Mβ3SnSnMe3 in the
presence of a palladium catalyst as hereinbefore described to prepare a suitable aryl stannane.
When Rb is a group R1 as hereinbefore defined reaction of a compound of the formula (7) with a compound of the formula (8) results directly in compounds of the formula (1).
An example of a precursor for R1 is when RD is hydrogen. In this situation reaction of a compound of the formula (7) with a compound of the formula (8) or a chemical equivalent
thereof results in a compound of the formula (2) or a compound of the formula (6) wherein R13 is hydrogen. Such compounds can then be converted into a compound of the formula (1) as herein described.
Other precursors for R1 include CN, CHO or COMe. Reaction of a compound of the formula (7) wherein Rb represents such a precursor with a compound of the formula (8) or a chemical equivalent thereof results in a compound of the formula (4) or a compound of the formula (6) wherein R12 or R13 is CN,
CHO or COMe. Such compounds can be converted to compounds of the formula (1) as herein described.
If desired a compound of the formula (1) wherein R1 is A0CO2H can be converted to the corresponding compound wherein R1 is A0CO2R9 by reaction with a compound R9OH wherein R9 is as hereinbefore defined.
A compound of the formula (1) wherein R0 is OH can be
converted to the corresponding compound where R0 is OR8 by reaction with R8L2 wherein R8 is as hereinbefore defined and L2 is a leaving group such as halo e.g. bromo, chloro, iodo.
If desired a compound of the formula (1) wherein R1 is
P (Z) (OR2) (OH) can be converted to the corresponding compound wherein R1 is P (Z) (OR2) (OR10) by reaction with a suitable O-protecting agent in standard manner. For example the compound can be reacted with a pivalolyloxymethyl halide. A compound of the formula (1) wherein R1 is 5-tetrazole can be reacted with a suitable N-protecting agent in standard manner, for example with a pivalolyloxymethyl halide.
A compound of the formula (1) wherein R1-R0 is A1CO2 is suitably prepared by heating a compound of the formula (1) wherein R1 is A1CO2H and R0 is OH with a dehydrating agent such as acetic anhydride, at an elevated temperature (e.g. 40 - 200°C), preferably at the reflux temperature of the
reaction mixture.
A compound of the formula (1) wherein R1-R0 is A2OCH2O is suitably prepared by reacting a compound of the formula (1) wherein R1 is A2OH and R0 is OH with a dihalomethane such as diiodo- or dibromomethane in the presence of silver carbonate in an organic solvent such as dimethylformamide at an
elevated temperature (e.g. 40 - 120°C).
A compound of the formula (2) is suitably prepared by
reacting a compound of the formula (6) wherein R13 is
hydrogen with an O-methylating agent such as
dimethylformamide dimethylacetal in dimethylformamide or trimethylphosphite at an elevated temperature (e.g. 40 - 120°C) or with iodomethane and silver carbonate in toluene or chloroform. This method can also be used for converting compounds of the formula (6) into corresponding compounds of the formula (4) and compounds of formula (7) wherein Ra is hydroxy into corresponding compounds wherein Ra is OR11. A compound of the formula (6) wherein R13 is acetyl can also be prepared by reacting a compound of the formula (6) wherein R13 is cyano with methyl lithium followed by aqueous acidic work up with for example hydrochloric acid. A compound of the formula (6) wherein R13 is hydrogen can be prepared by reacting a compound of the formula (6) wherein R13 is cyano with orthophosphoric acid at an elevated
temperature, e.g. 50 - 200°C. A compound of formula (4) wherein R12 is cyano is suitably prepared by reacting the anion of a compound of formula (2) wherein Ar and R11 are as hereinbefore defined with
dimethylformamide with cooling (e.g. -80 to 10°C), followed by ambient temperature and aqueous work-up. The resulting compound of formula (4) wherein R12 is carboxaldehyde is treated with hydroxylamine hydrochloride and sodium acetate in a suitable solvent such as ethanol or methanol at elevated temperature, e.g. 40-100°C, preferably at the reflux
temperature of the reaction mixture followed by dehydrating
the product obtained for example by heating with acetic anhydride.
A compound of the formula (6) wherein R13 is cyano or acetyl and Ar is as hereinbefore defined can be suitably prepared by reaction of a compound of formula (4) wherein R12 is cyano or acetyl and R11 and Ar are as hereinbefore defined with a demethylating agent such as sodium
iodide/chlorotrimethylsilane in the absence of solvent or in an organic solvent such as acetonitrile or chloroform at an elevated temperature (e.g. 40 to 100°C) or at ambient
temperature.
A compound of the formula (6) wherein R13 is P (O) (OR2)2 can be prepared by treating a compound of the formula (2) wherein R11 is P(O)(OR2)2 with a strong base such as lithium
diisopropylamide in an organic solvent such as
tetrahydrofuran with cooling (e.g. -100-0°C). A compound of the formula (2) wherein R11 is P (O) (OR2)2 is suitably prepared by treating a compound of the formula (6) wherein R13 is hydrogen with a compound of the formula (9) :
L3p(O) (OR2)2 (9) wherein L3 is a leaving group and R2 is as hereinbefore defined with a base such as diisopropylethylamine.
Suitably L3 is halo, for example chloro or bromo.
A compound of formula (2) wherein R11 is P (O) (OR2)2 can also be prepared by treating a compound of the formula (6) wherein R13 is hydrogen with a compound of the formula (10): HP (O) (OR2)2 (10) wherein R2 is as hereinbefore defined in the presence of an amine base such as triethylamine, and carbon tetrachloride.
Alternatively, a compound of the formula (6) wherein R13 is P (O) (OR2) 2 is suitably prepared by treating a compound of the formula (6) wherein R13 is hydrogen with a compound of the formula (9) in the presence of a strong base such as lithium diisopropylamide in an organic solvent such as
tetrahydrofuran with cooling (e.g. -100-0°C) without
isolation of the intermediate compound of the formula (2) wherein R11 is P (O) (OR2)2. A compound of formula (6) wherein R13 is hydrogen is suitably prepared by demethylating a compound of formula (2) as hereinbefore defined. Suitably a compound of formula (2) is treated with boron tribromide in an organic solvent such as dichloromethane or toluene with cooling (e.g. -80 to 10°C) followed by ambient temperature and aqueous work-up. Or a compound of formula (2) is treated with sodium iodide and chlorotrimethylsilane at ambient or elevated temperature (e.g. 40-80°C) conveniently ambient temperature in a solvent such as acetonitrile or dichloromethane.
A compound of the formula (6) wherein R13 is P (O) (NHR14) (OR2) can be prepared by reaction of a compound of the formula (6) wherein R13 is P (O) (OH) (OR2) with carbon tetrachloride, triphenylphosphine and aniline or a C1-4alkylamine in an organic solvent such as pyridine at ambient temperature or with cooling (e.g. -10 to 5°C). Alternatively a compound of the formula (6) where R13 is P (O) (OH) (OR2) can be reacted with dimethylformamide and oxalyl chloride in an organic solvent such as a halo hydrocarbon e.g. dichloromethane at ambient temperature, followed by reaction with aniline or a C1-4alkylamine preferably with cooling (-10 to 5°C).
Compounds of the formula (7) are known or can be prepared from a compound of the formula (11):
wherein Ra and L1 are as hereinbefore defined using similar methods to those described for preparing compounds of the formula (1).
Thus, a compound of the formula (7) wherein Rb is P (O) (OR2)2 can be prepared by reacting a compound of the formula (11) wherein Ra is OH with a compound of the formula (9) or (10) in similar manner to the reaction of a compound of the formula (6) wherein R13 is hydrogen with a compound of the formula (9) or (10). If desired the group Ra can then be converted to OMe.
Similarly, a compound of the formula (11) where Ra is OMe can be treated in the presence of a strong base with a compound of the formula (3), a compound of the formula (5) , sulphuryl chloride, sulphur dioxide or dimethylformamide to prepare a compound of the formula (7) wherein Rb is CR3(OR4)CO2R9, COCO2R9, SO3H, SO2H, or CHO respectively in similar manner to the corresponding reaction with a compound of the formula (2) as hereinbefore described. Particularly suitable as a strong base is lithium tetramethyl piperidide.
A compound of the formula (8) is suitably prepared by
reacting the organolithium or Grignard reagent, formed from a compound of the formula (12):
Ar-L4 (12) wherein L4 is bromo or iodo and Ar is as hereinbefore defined with a tri-C1-4alkylborate such as trimethyl, tri-isopropyl
or tri-n-butyl borate in an organic solvent such as diethyl ether or tetrahydrofuran with cooling (e.g. - 80-10°C).
The Ar group in compounds of the formula (2), (4), (6) or (12) preferably (2) or (4) may be appropriately
functionalised by methods of aromatic substitution known in the art. For example, a bromo group may be introduced into a suitably substituted phenyl ring (eg. disubstituted in the 2- and 4-positions by electron-donating groups such as
C1-6alkoxy) by reaction with a brominating agent such as N-bromosuccinimide or bromine in a solvent such as
dimethylformamide. Alternatively a nitro group can be introduced into a phenyl ring by reaction with a suitable nitrating agent, such as nitronium tetrafluoroborate. Such a group can be readily hydrogenated to an amino group which if desired can be converted to a NHCOR7 group by reaction with LCOR7 wherein L is a leaving group and R7 is as hereinbefore defined. Suitable examples of the reagent LCOR include acid halides (L is halo eg. chloro or bromo) or acid anhydrides (L is OCOR7).
Other suitable functionalisations include the introduction of an allyl group ortho to a hydroxy substituent on a phenyl ring by reaction with an allyl halide, eg. bromide, to form an allyloxy derivative which on heating undergoes a Claisen rearrangement to form an ortho allyl hydroxy derivative. The hydroxy group can in turn be functionalised, eg. by reaction with a C1-6alkyl halide to form a C1-6alkoxy group. If desired, an allyl group can be converted to an E-1-propenyl group by reaction with a strong base, such as sodium
methoxide. An E-1-propenyl group can be cleaved to a formyl group by reaction with an oxidising agent such as
N-methylmorpholine-N-oxide in the presence of a catalyst such as osmium tetroxide to form a 1,2,dihydroxypropyl group which on reaction with an oxidising agent such as sodium periodate forms the formyl group. Alternatively the E-1-propenyl group can be converted directly to a formyl group by reaction with a mixture of osmium tetroxide and sodium periodate or by reaction with ozone. A formyl group can in turn be further
functionalised, for example it can be converted to a
hydroxymethyl group by reaction with a suitable reducing agent such as sodium borohydride, the hydroxymethyl group then being reacted further, eg. with a C1-6alkyl halide to form a C1-6alkoxymethyl group. Alternatively a formyl group can be reacted with a suitable Horner Wittig or Wittig reagent such as (R15O)2P(O)CH2CO2R15 or Ph3P=CHCO2R15 wherein R15 is C1-4alkyl to form a CH=CHCO2R15 group which can be optionally hydrolysed to a -CH=CHCO2H group. A -CH=CHCO2R15 group can be converted to a -CH=CHCON(R7)2 group by reaction with an amine HN(R7)2 or a chemical equivalent thereof wherein R7 is as hereinbefore defined. Alternatively a
-CH=CHCO2H group can be converted to an acid halide, eg. the acid chloride by reaction with oxalyl chloride, which can then be reacted with an amine HN(R7)2 or a chemical
equivalent thereof. An example of a chemical equivalent is ammonium hydroxide which will form a CH=CHCONH2 group.
Pharmaceutically acceptable base addition salts of the compounds of the formula (1) may be prepared by standard methods, for example by reacting a solution of the compound of the formula (1) with a solution of the base.
The following biological test methods, data and Examples serve to illustrate this invention.
Cyclic-AMP Protein Kinase (cA-PrK) Agonist Activity
Type II cA-PrK was prepared from the cardiac muscle of a cow. The supernatant from a muscle homogenate (3 mis of 10 mM potassium phosphate, 1 mM EDTA per g tissue) was applied to a column of DEAE-cellulose equilibrated with the homogenisation buffer and the type II cA-PrK was eluted with homogenisation buffer containing 350 mM sodium chloride (Rannels et al., 1983, Methods Enzymol., 99, 55-62).
Type II cA-PrK was assayed for phosphotransferase activity by incubating the enzyme at 30°C for 5 minutes with
[γ-32P]-adenosine triphosphate and a suitable peptide
substrate such as malantide (Malencik et al., 1983, Anal. Biochem., 132, 34-40). The reaction was terminated by the addition of hydrochloric acid and the [32P]-phosphopeptide quantified by spotting the reaction mixture onto
phosphocellulose papers. The concentration of compound required to give 10% phosphotransferase activation is given as the EC10 (μM). The compounds of Examples 1 and 2 had EC10 values of 2.6 and 1.0 μM respectively. Inhibition of Platelet Aggregation
Human platelet-rich-plasma was separated from freshly drawn blood (in acid/citrate/dextrose) and treated with 100 μM acetylsalicylic acid for 15 minutes at 37°C. A washed platelet suspension was then prepared in a Hepes-isotonic saline buffer after a single centrifugation step and adjusted to a concentration of 1.5×108 cells/ml. Aliquots of this suspension were pre-incubated with compounds for 5 minutes at 37°C, then challenged with 1.0 μM U46619. The extent of aggregation after 2 minutes were expressed as a percentage of control and results obtained are expressed as an IC50
(concentration to cause 50% inhibition of platelet
aggregation, μM). The compounds of Examples 1 and 2 had IC50 values of 20 and 38 μM respectively.
Inhibition of Spontaneous Contraction in Guinea-Pig Colon
Segments of isolated guinea-pig colon (2 cm) were suspended under 2 g tension in standard organ baths containing Krebs solution. The tissues were connected at the free end to isometric transducers which allow recording and display of developed tension on chart recorders. On-line computer capture and analysis was used to quantify the effects of test compounds on spontaneous contractions. Inhibitory responses were calculated as % maximum inhibition of spontaneous contraction distance over 3 consecutive pre and post dose 2 minute readings. The concentration of compound which caused 50% inhibition of the spontaneous contraction is given as the EC50 (μM).
Bronchodilatation - In vitro
Spiral strips of guinea-pig trachea were suspended in standard organ baths containing Krebs solution. The tissues were connected at the free end to isometric transducers which allow recording and display of developed tension on chart recorders. Tension was allowed to develop spontaneously and concentrations of test compounds added in a cumulative fashion. The concentration of compound which caused 50% inhibition of the spontaneously developed tension is given as the IC50 (μM).
Measurement of cardiac muscle relaxation time in rabbit ventricle
Papillary muscles from the right ventricle of female Albino New Zealand rabbits are mounted in standard organ baths containing oxygenated Krebs solution. One end of the muscle is connected to an isometric transducer which allowed
recording of contractile force and its first derivative on chart recorders. Test compounds are added to the bath in a cumulative manner. Relaxation time is calculated as the time taken from peak tension to the end of the contraction.
Compounds which cause a decrease in the relaxation time indicate a positive lusitropic effect of use in the treatment of cardiovascular diseases where there is a component of diastolic failure such as congestive heart failure, angina, hypertension and cardiomyopathy.
Example 1
2-(5-Tetrazolyl)-5-(2,3-di-n-propoxyphenyl)phenol (a) From 1,2-di-n-propoxybenzene (13.8g), 2,3-di-n- propoxyphenylboronic acid (13g) was prepared according to the method of W. J. Thompson and J. Gaudino J. Org. Chem. 1984, 49, 5237. (b) To methyl 2,4-dihydroxybenzoate (5.95g) and 4-N,N- dimethylaminopyridine (8.65g) in dichloromethane at -50°C, trifluoromethanesulphonic anhydride (10.0g) was added over 5mins. The mixture was warmed to room temperature stirred for 1 hour, treated with 2N hydrochloric acid and the organic phase separated, dried (MgSO4) and solvent removed at
reduced pressure. The residue was column chromatographed (silica gel, diethyl ether/petroleum ether eluant) to give methyl 2-hydroxy-4-trifluoromethanesulphonyloxy benzoate (5.0g) 1H NMR (CDCl3) 3.99(s,3H), 7.25(d<1H), 7.44(dd,1H) and 8.23 (d,1H).
(c) From methyl 2-hydroxy-4-trifluoromethanesulphonyloxy benzoate (8.7g) and 2,3-di-n-propoxyphenylboronic acid (7.4g) and using the method of A. Huth, I. Beetz and I. Schumann, Tetrahedron, 1989, 45, 6679, methyl 2-hydroxy-4-(2,3-di-n-propoxyphenyl)benzoate (4.6g) was prepared. 1H NMR (CDCl3) 0.82(t,3H), 1.08(t,3H), 1.48-1.59 (m, 2H), 1.81-1.95 (m, 2H), 3.70(t,2H), 3.96(s,3H), 3.98(t,2H), 6.93(d,2H), 7.07-7.17(m,3H), 7.83(d,1H) and 10.76 (s, 1H).
(d) Methyl 2-hydroxy-4-(2,3-di-n-propoxyphenyl)benzoate (2.2g) in ethanol (15ml) and dioxane (30ml) was treated with sodium borohydride (lg) and stirred at room temperature for 48 hours. Solvent was removed at reduced pressure and the residue column chromatographed (silica gel, dichloromethane eluant) to give 2-hydroxy-4-(2,3-di-n-propoxyphenyl)benzyl alcohol (1.7g). The benzyl alcohol was oxidised according to the method of S. V. Ley et al J. C. S. Chem. Comm., 1987, 1625 to give 2-hydroxy-4-(2,3-di-n-propoxyphenyl)-
benzaldehyde (0.78g). 1H NMR (CDCl3) 0.82(t,3H), 1.08(t,3H), 1.41-1.62 (m,2H), 1.84-1.95 (m,2H), 3.72 (t,2H), 3.99(t,2H), 6.91-6.96(m,2H), 7.09(t,1H), 7.18(s,1H), 7.26(dd,1H),
9.92(s,1H) and 11.06 (s,1H).
(e) A solution of 2-hydroxy-4-(2,3-di-n-propoxyphenyl)- benzaldehyde (0.78g) in ethanol (15ml) and saturated aqueous sodium acetate (8ml) containing hydroxylamine hydrochloride (0.23g) was stirred for 16 hours. Solvent was removed at reduced pressure acetic anhydride added and the mixture boiled for 4 hours. Solvent was removed at reduced pressure, the residue dissolved in diethyl ether (50ml) and washed with water (2 × 50ml). The organic layer was dried (MgSO4) and solvent removed at reduced pressure to give 2-hydroxy-4-(2,3- di-n-propoxyphenyl)benzonitrile (0.8g). IR (nujol mull)
2,230cm-1.
(f) A mixture of 2-hydroxy-4-(2,3-di-n-propoxyphenyl)- benzonitrile (0.8g), sodium azide (0.38g) and ammonium chloride (0.35g) in N-methylpyrrolidinone (20ml) was heated at 130°C for 3 hours. The reaction mixture was absorbed onto silica gel and column chromatographed (silica gel, diethyl ether then diethyl ether/methanol 85/15 eluant). Appropriate fractions were combined, solvent removed at reduced pressure and the residue triturated with water to give the title compound (0.26g) m.p. 187-189°C.
Example 2 Ethyl 2-hydroxy-4-(2,3-di-n-propoxyphenyl)phenyl phosphonate
(a) From 3-bromophenol (1.73g) and 2,3-di-n-propoxyphenylboronic acid (2.38g), 3-(2,3-di-n-propoxyphenyl)phenol m.p. 78-80°C after column chromatography (silica gel, diethyl ether/petroleum ether 1:9 eluant) was prepared according to the method of Example 1 (c).
(b) From 3-(2,3-di-n-propoxyphenyl)phenol (1.0g), diethyl 3-(2,3-di-n-propoxyphenyl) phenyl phosphate (1.2g) was
prepared according to the method of G. W. Kenner and N. R. Williams J. Chem. Soc. 1955, 522.
(c) Diethyl 3-(2,3-di-n-propoxyphenyl)phenyl phosphate (1.2g) was rearranged to diethyl 2-hydroxy-4-(2,3-di-n- propoxyphenyl)phenyl phosphonate according to the method of L. S. Melvin Tet. Letters, 1981, 22, 3375 and subsequently hydrolysed to the title compound, isolated as an oil, by boiling with 5N aqueous sodium hydroxide (10ml). 1H NMR (DMSO-d6) 0.75(t,3H), 1.05(t,3H), 1.20(6H), 1.43-1.53 (m, 2H), 1.54-1.83(m,2H), 3.72(t,2H, 3.86-3.92 (m, 4H), 4.03(t,2H), 6.88-7.66(m,5H) and 7.46 (dd, 1H).
Example 3
Pharmaceutical compositions for oral administration are prepared by combining the following :
% w/w
2-(5-tetrazolyl)-5- (2,3-dipropoxyphenyl)phenol 0.5 3.0 7.14
2% w/w Soya lecithin in soya
bean oil 90.45 88.2 84.41
Hydrogenated vegetable
shortening and beeswax 9.05 8.8 8.45 The formulations are then filled into individual soft gelatin capsules.
Example 4 A pharmaceutical composition for parenteral administration is prepared by dissolving ethyl 2-hydroxy-4-(2,3-dipropoxyphenyl)phenyl phosphonate (0.02 g) in polyethylene glycol 300 (25 ml) with heating. This solution is then diluted with water for injections Ph. Eur. (to 100 ml). The
solution is then sterilised by filtration through a 0.22 micron membrane filter and sealed in sterile containers.
Claims (10)
1. A compound of the formula (1)
or a pharmaceutically acceptable salt thereof, wherein :
R0 is OH or a bioprecursor thereof,
R1 is A0CO2H, P(Z) (OH) (OR2), SO2H, SO3H or 5-tetrazolyl or a bioprecursor thereof,
A0 is CH2, CHF, CF2, CR3(OR4), CO or C(OR5) (OR6),
R2 is phenyl, C3-5cycloalkyl, C3-5CycloalkylC1-4alkyl, or C1-8alkyl optionally substituted by C1-4alkoxy,
R3 is H, methyl or ethyl,
R4 is H or C1-3alkyl, R5 and R6 are each C1-3alkyl or together form a 1,2- ethanediyl group or 1, 3-propanediyl group.
Z is O or S, and Ar is phenyl optionally substituted by one to three groups independently selected from C1-6alkyl, C2-6alkenyl, C1-6alkoxy, C3-6alkenyloxy, C3-6cycloalkyl,
C3-6cycloalkoxy, C1-6alkylthio, phenyl, phenylthio, benzyloxy, C1-6polyfluoroalkyl, C1-6polyfluoroalkoxy, halo, N(R7)2 or NHCOR7 wherein R7 is H or C1-6alkyl, or -X(CH2)nY- attached to adjacent carbon atoms of the phenyl ring wherein X and Y are independently CH2 or 0 and n is 1 to 3, wherein said C1-6alkyl, C2-6alkenyl or C1-6alkoxy groups can be independently substituted by OH, C1-6alkoxy, C3-6cycloalkyl, N(R7)2, CO2R7 or CON(R7)2.
2. A compound according to claim 1 wherein R1 is AOCO2H or A0CO2R9 in which R9 is an ester-forming group.
3. A compound according to claim 1 wherein R1 is P(Z) (OH) (OR2) or P(Z) (OR2)2.
4. A compound according to claim 1 wherein R1 is SO2H, SO3H or 5-tetrazolyl.
5. A compound according to claim 1 wherein R1 and R0 are linked together such that R1-R0 is A1CO2
in which A1 is CH2, CHF, CF2, CR3(OR4), CO or C(OR5) (OR6).
6. A compound according to claim 1 wherein R1 and R0 are linked together such that R1-R0 is A2OCH2O in which A2 is P (Z) (OR2) or CR3(CO2R9) and R9 is an ester-forming group.
7. A compound according to claim 1 which is :
2-(5-tetrazolyl)-5-(2,3-dipropoxyphenyl)phenol, or ethyl 2-hydroxy-4-(2,3-dipropoxyphenyl)phenyl phosphonate, or a pharmaceutically acceptable salt thereof.
8. A compound according to any one of claims 1 to 7 for use as a medicament.
9. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 7 and a
pharmaceutically acceptable carrier.
10. A process for preparing a compound of the formula (1) as defined in claim 1 or a pharmaceutically acceptable salt thereof which process comprises : a) for compounds wherein R1 is A0CO2H or A0CO2R9 and : i) A0 is CR3(OR4),
reacting in the presence of a strong base a compound of the formula (2) :
wherein R11 is methyl and Ar is as defined in claim 1, with a compound of the formula (3) :
R3COCO2R9 (3) wherein R3 is as defined in claim 1 and R9 is an esterforming group to form a compound of the formula (4) :
wherein R12 is CR3(OH)CO2R9 and R3, R9, R11, and Ar are as hereinbefore defined and thereafter optionally reacting with a C1-3alkylating agent to form the corresponding compound wherein R12 is CR3 (OC1-3alkyl)CO2R9, ii) A0 is CO,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with a compound of the formula (5) :
R9O2CCO2R9 (5) wherein R9 is as hereinbefore defined to form a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11 and Ar are as hereinbefore defined, iii) A0 is CH(OH),
reacting a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a reducing agent to form the corresponding compound wherein R12 is CH(OH)CO2R9, iv) A0 is CH2,
reacting a compound. of the formula (4) wherein R12 is COCO2H or COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a suitable reducing agent to form the corresponding compound wherein R12 is CH2CO2H, v) A0 is C(OR5) (OR6),
reacting a compound of the formula (4) wherein R^2 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a
Cl-3alcohol, 1,2-ethanediol or 1,3-propanediol to form the corresponding compound wherein R12 is C(OR5) (OR6)CO2R9, vi) A0 is CF2,
reacting a compound of the formula (4) wherein R12 is COCO2R9 and R9, R11, and Ar are as hereinbefore defined with a
fluorinating agent to form the corresponding compound wherein R11 is CF2CO2R9, or vii) A0 is CHF, reacting a compound of the formula (4) wherein R12 is
CH(OH)CO2R9 and R9, R11, and Ar are as hereinbefore defined with a fluorinating agent to form the corresponding compound wherein R12 is CHFCO2R9, and thereafter optionally :
° converting the group OR11 into OH ° converting the group A0CO2R9 into A0CO2H; or b) for compounds wherein R1 is CH2CO2H,
converting a compound of the formula (6) :
wherein R13 is acetyl and Ar is as hereinbefore defined into the corresponding compound wherein R13 is CH2CO2H; or c) for compounds wherein R1 is CH(OR4)CO2H reacting a compound of the formula (4) wherein R12 is -CH(OH)CN with a C1-3alkylating agent and/or converting the group CN into CO2H, and optionally converting the group OR11 into OH; or d) for compounds wherein R1 is P (O) (OH) (OR2), hydrolysing a compound of the formula (6) wherein R13 is P (O) (OR2)2, R2 is as defined in claim 1 and Ar is as hereinbefore defined; or e) for compounds wherein R1 is P(S) (OH) (OR2), converting a compound of the formula (6) wherein R13 is P (O) (NHR14) (OR2) and R14 is phenyl or C1-4alkyl and Ar is as hereinbefore defined into the corresponding compound wherein R13 is
P(S) (OH) (OR2); or f) for compounds where R1 is SO3H,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with sulphuryl chloride or a chemical equivalent thereof and optionally converting the group OR11 into OH; or g) for compounds wherein R1 is SO2H,
reacting in the presence of a strong base a compound of the formula (2) as hereinbefore defined with sulphur dioxide and optionally converting the group OR11 into OH; or h) for compounds wherein R1 is 5-tetrazolyl, reacting a compound of the formula (4) wherein R12 is cyano and R11 is as hereinbefore defined or benzenesulphonyl, or a compound of the formula (6) wherein R12 is cyano with an azide salt and thereafter if necessary converting the group OR11 into OH; or i) for compounds wherein R1 is as defined for compounds of the formula (1) reacting in the presence of a palladium catalyst a compound of the formula (7):
wherein Rb is a group R1 as defined in claim 1 or a precursor thereof and Ra is R0 or OR11 as hereinbefore defined and L1 is a leaving group with a compound of the formula (8) :
ArB(OH)2 (8) or a chemical equivalent thereof wherein Ar is as
hereinbefore defined and then, if necessary, converting a precursor of R1 into R^ and/or converting the group OR11 into OH, and optionally thereafter :
° forming a bioprecursor of R0 and/or R1 ° forming a pharmaceutically acceptable salt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9124579 | 1991-11-20 | ||
GB919124579A GB9124579D0 (en) | 1991-11-20 | 1991-11-20 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2927492A true AU2927492A (en) | 1993-06-15 |
Family
ID=10704882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29274/92A Abandoned AU2927492A (en) | 1991-11-20 | 1992-11-16 | Phenol derivatives as agonists of a cyclic amp dependent protein kinase |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0620815A1 (en) |
JP (1) | JPH07503235A (en) |
AU (1) | AU2927492A (en) |
CA (1) | CA2124003A1 (en) |
GB (1) | GB9124579D0 (en) |
MX (1) | MX9206709A (en) |
NZ (1) | NZ245168A (en) |
PT (1) | PT101073A (en) |
TW (1) | TW221812B (en) |
WO (1) | WO1993010107A1 (en) |
ZA (1) | ZA928894B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3590082A (en) * | 1967-10-06 | 1971-06-29 | Merck & Co Inc | 4-(p-fluorophenyl)salicylamide derivatives |
EP0532531A1 (en) * | 1990-05-21 | 1993-03-24 | Smith Kline & French Laboratories Limited | Phenol and pyridinol derivatives as pharmaceuticals |
-
1991
- 1991-11-20 GB GB919124579A patent/GB9124579D0/en active Pending
-
1992
- 1992-11-16 EP EP92923480A patent/EP0620815A1/en not_active Withdrawn
- 1992-11-16 AU AU29274/92A patent/AU2927492A/en not_active Abandoned
- 1992-11-16 CA CA002124003A patent/CA2124003A1/en not_active Abandoned
- 1992-11-16 JP JP5509095A patent/JPH07503235A/en active Pending
- 1992-11-16 WO PCT/GB1992/002119 patent/WO1993010107A1/en not_active Application Discontinuation
- 1992-11-18 NZ NZ245168A patent/NZ245168A/en unknown
- 1992-11-18 PT PT101073A patent/PT101073A/en not_active Application Discontinuation
- 1992-11-18 ZA ZA928894A patent/ZA928894B/en unknown
- 1992-11-19 MX MX9206709A patent/MX9206709A/en unknown
- 1992-11-19 TW TW081109264A patent/TW221812B/zh active
Also Published As
Publication number | Publication date |
---|---|
GB9124579D0 (en) | 1992-01-08 |
PT101073A (en) | 1994-02-28 |
MX9206709A (en) | 1993-05-01 |
EP0620815A1 (en) | 1994-10-26 |
TW221812B (en) | 1994-03-21 |
WO1993010107A1 (en) | 1993-05-27 |
JPH07503235A (en) | 1995-04-06 |
NZ245168A (en) | 1995-06-27 |
ZA928894B (en) | 1994-05-18 |
CA2124003A1 (en) | 1993-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0550576A1 (en) | Phenylpyridinol derivatives as medicaments | |
JP5048017B2 (en) | Substituted phenylalkanoic acid derivatives and uses thereof | |
US20090312315A1 (en) | Pai-1 inhibitor | |
AU642743B2 (en) | Phenol and pyridinol derivatives as pharmaceuticals | |
KR20010020472A (en) | Novel thyroid receptor ligands and method | |
JPH0822865B2 (en) | Phenol-substituted gem-diphosphonate derivative, its preparation method and pharmaceutical composition containing the same | |
AU2930392A (en) | 3-pyridinol derivatives and their use as medicaments | |
JP3300369B2 (en) | Process for producing 2-aryl-3-aryl-5-halopyridines useful as COX-2 inhibitors | |
AU2927492A (en) | Phenol derivatives as agonists of a cyclic amp dependent protein kinase | |
US5670493A (en) | Aminophenylphosphonic acid compounds | |
CN110590548A (en) | AKR1C3 inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | |
US4016223A (en) | Prostaglandin dehydrogenase inhibiting agents | |
AU654051B2 (en) | Pyridinol derivatives as medicaments | |
WO1993010093A1 (en) | 2-pyridinol derivatives and their use as medicaments | |
US4038415A (en) | Prostaglandin dehydrogenase inhibiting agents |